Digestive System Neuroendocrine Neoplasm

cancer family

Identifier: CI-CAN-00000164
Entity page: /cancer/digestive-system-neuroendocrine-neoplasm ↗
Edges: 365

Neighbours: 3 genes15 drugs10 trials
Drawn: 28 of 28 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Digestive System Neuroendocrine Neoplasm altered in cohorts of …ALTERED_INderived3 of 3
← altered in cohorts of	MEN1 36 / 98 cases (37 %) · ssm · panet_arcnet_2017 · largest of 2 cohorts	—	—	Pancreatic Neuroendocrine Tumor	2	Observed	cbioportal	graph →
← altered in cohorts of	DAXX 22 / 98 cases (22 %) · ssm · panet_arcnet_2017 · largest of 2 cohorts	—

Digestive System Neuroendocrine Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 67show all (up to 200)
→ investigated in trials for	Everolimussmall molecule 20 trials (5 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neuroendocrine Neoplasm	20	Observed	clinicaltrials	graph →
→ investigated in trials for	Temozolomidesmall molecule 11 trials (4 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neuroendocrine Neoplasm	11	Observed	clinicaltrials	graph →
→ investigated in trials for	Lutetium (177lu) Oxodotreotideother 10 trials (8 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neuroendocrine Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Sunitinibsmall molecule 10 trials (3 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neuroendocrine Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Cabozantinibsmall molecule 8 trials (6 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neuroendocrine Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall molecule 8 trials (4 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neuroendocrine Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 7 trials (2 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neuroendocrine Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 7 trials (4 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neuroendocrine Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 7 trials (4 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neuroendocrine Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 6 trials (4 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neuroendocrine Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Fluorouracilsmall molecule 6 trials (0 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neuroendocrine Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Irinotecansmall molecule 6 trials (0 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neuroendocrine Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 5 trials (3 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neuroendocrine Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Ipilimumabmonoclonal antibody 4 trials (3 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neuroendocrine Neoplasm	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Leucovorinsmall molecule 4 trials (0 active) · roll-up of the cancer and its descendants	—	—	Digestive System Neuroendocrine Neoplasm	4	Observed	clinicaltrials	graph →

Digestive System Neuroendocrine Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 67show all (up to 200)

→ investigated in trials for

Everolimussmall molecule

20 trials (5 active) · roll-up of the cancer and its descendants

—

Digestive System Neuroendocrine Neoplasm

Observed

Digestive System Neuroendocrine Neoplasm studied in …STUDIED_INderived10 of 295show all (up to 200)
→ studied in	NCT00001276recruiting Diagnosing and Treating Low Blood Sugar Levels · condition mapped ALIAS · 295 trials mapped (99 active)	—	—	Pancreatic Insulinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05196087recruiting Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!) · condition mapped ALIAS · 295 trials mapped (99 active)	—	—	Digestive System Neuroendocrine Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT04924075Phase 2 · recruiting Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) · condition mapped ONTOLOGY_EXACT · 295 trials mapped (99 active)	—	—	Pancreatic Neuroendocrine Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT07842172Phase 3 · not yet recruiting Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms · condition mapped ALIAS · 295 trials mapped (99 active)	—	—	Digestive System Neuroendocrine Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03866382Phase 2 · recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 295 trials mapped (99 active)	—	—	Bladder Small Cell Neuroendocrine Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05773274Phase 2 · recruiting Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial · condition mapped CURATED_BROADER · 295 trials mapped (99 active)	—	—	Digestive System Neuroendocrine Tumor G1	1	Observed	clinicaltrials	graph →
→ studied in	NCT03967951completed CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms · condition mapped ONTOLOGY_EXACT · 295 trials mapped (99 active)	—	—	Pancreatic Neuroendocrine Tumor	1	Observed	clinicaltrials	graph →
→ studied in	NCT03375320Phase 3 · active not recruiting Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors · condition mapped CURATED_BROADER · 295 trials mapped (99 active)	—	—	Digestive System Neuroendocrine Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03950609Phase 2 · active not recruiting Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors · condition mapped ONTOLOGY_EXACT · 295 trials mapped (99 active)	—	—	Digestive System Neuroendocrine Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04234568Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors · condition mapped CURATED_BROADER · 295 trials mapped (99 active)	—	—	Digestive System Neuroendocrine Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains